Innate Pharma, S.a.

Innate Pharma S.a.s.

Novo Nordisk A/s

University of Genova

Novo Nordisk-a/s Novo Alle

University of Genoa

Novo Norkisk A/s

Paul Scherrer Institut

Innate Pharma

Universita Di Genova

Università Degli Studi Di Perugia

Francois Romagne

Alessandro Moretta

Pascale Andre

Peter Andreas Nicolai Reumert Wagtmann

Andrea Velardi

Joakim Glamann

Kristian Kjaergaard

Stefan Zahn

Anders Svensson

Mariella Della Chiesa

Ivan Svendsen

Emanuela Marcenaro

Matthias Thorolfsson

Laurent Gauthier

Roger Schibli

Mathieu Blery

Christian Belmant

Petrus Johannes Louis Spee

Delphine Bregeon

Patrick Dennler

Eliane Fischer

Soren Berg Padkjaer

Pieter Spee

Soeren Berg Padkaer

Michael Wilken

Ulrik Morch

Matthias Thórólfsson

Milchael Wilken

Petrus Johannes Loius Spee

Laurant Gauthier

Pieter Johannes Louis Spee

Soren Berg Padkaer

Peter Andreas Wagtmann

Søren Berg Padkaer

Compositions comprising anti-KIR antibodies and one or more secondary anti-cancer agents or anti-viral agents and methods of using such combinations (as combination compositions or in separate administration protocols) in the treatment of cancers (e.g., lung cancer) or viral infection (e.g., HIV or HCV infection) are provided.

Anti-KIR combination treatments and methods

The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders.

Monoclonal antibodies against NKG2A

The present invention relates, generally, to methods and compositions for increasing the efficiency of therapeutic antibodies. Their efficiency is enhanced through the increase of the ADCC mechanism. More particularly, the invention relates to the use of a therapeutic antibody in combination with compounds that block an inhibitory receptor or stimulate an activating receptor of an NK cell in order to enhance the efficiency of the treatment with therapeutic antibodies in human subjects.

Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds

The present invention relates to methods of treating proliferative disorders, particularly immunoproliferative and autoimmune disorders, and methods of producing antibodies which bind NK cell receptors for use in therapeutic strategies for treating such disorders, particularly to deplete cells involved in the immunoproliferative pathology.

Compositions and methods for treating proliferative disorders

Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus.

Methods of enhancing antibody-based antiviral therapies by administering KIR2DL-binding antibodies

This invention relates to compounds that inhibit KIR2DL1, 2 and/or 3 polypeptide comprising compounds (e.g., anti-KIR2DL1, 2, and/or 3 antibodies) that neutralize NK cell inhibitory receptors and methods of using such compounds and compositions containing in the treatment and prevention of inflammatory or autoimmune disorders.

Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders

Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

Human anti-KIR antibodies

Nucleic acids encoding human anti-kir antibodies

Methods of treating viral infections by administering KIR2DL-binding antibodies

Growing community of inventors

La Ciotat, France

Francois Romagne